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Introduction
This review was prepared to provide a basic
overview of “Other Blood Groups.” Some of the more
major blood group systems, i.e., ABO, Rh, Kell, Duffy,
and Kidd, are also reviewed in this issue and are not
covered here. The sheer mass of data on the MNS
blood group system is so extensive and complicated
that it justifies a review all of its own,and it is therefore
not discussed in this article. However, various aspects
of MNS were described in recent papers in
Immunohematology.1,2
The blood group systems that are covered are those
that most workers believe to have some degree of
clinical importance or interesting features: Diego (DI),
Yt (YT),Xg (XG),Scianna (SC),Dombrock (DO),Colton
(CO), Landsteiner-Wiener (LW), and Indian (IN).
Readers will find a brief digest of each blood group
system, which includes some historical, statistical,
genetic, biochemical, and serologic data. It was the
authors’ intention to compile data that could be
entitled:“Other Blood Groups:What you need to know
for the SBB exam.”1
Readers will note that there are only a few
references used in this review. Most of the information
given here has been dissected from the books listed in
the fourth and fifth references. Between them, they
contain a much more detailed, extensive, and
comprehensive review of the vast volume of material
available on these blood group systems. For additional
information or clarification, readers are strongly
encouraged to consult the aforementioned
publications. The additional references contain
pertinent newer information that has been reported
since the publication of the main sources of data.
Diego Blood Group System
The Diego blood group system (ISBT: DI/010) has
expanded from its humble beginnings to now include
up to 21 discrete antigens (Table 1).3 Band 3, an anion
exchange, multi-pass membrane glycoprotein, is the
basic structure that carries the Diego system antigenic
determinants.4 The gene that encodes the Band 3
protein is named SLC4A1 and its chromosomal location
is 17q12–q21.4
Dia and Dib are antithetical, resulting from a single
nucleotide substitution (2561T>C) that gives rise to
amino acid changes in the Band 3 protein (Leu854Pro).
To date, the Di(a–b–) phenotype has not been
described. The Dia and Dib antigens are resistant to
treatment with the following enzymes/chemicals:
ficin/papain, trypsin,α-chymotrypsin,DTT (0.2 M), and
chloroquine.4 The only other pair of antithetical
antigens in the system are Wra and Wrb, the result of
another nucleotide substitution (1972A>G) that
produces another change in Band 3 (Lys658Glu).4 The
extremely rareWr(a–b–) phenotype has been found in
persons with rare glycophorin variants, where
expression of the Wrb antigen is dependent upon the
presence of functional glycophorin A.5 The Wra and
Wrb antigens are resistant to treatment with the
following enzymes/chemicals: ficin/papain, trypsin, α-
chymotrypsin, DTT (0.2 M), and chloroquine.4
The other antigens in this system are of extremely
low frequency and are usually the result of single
nucleotide substitutions. Interestingly, many of the
antibodies directed against these low-frequency
antigens show some degree of crossreactivity or other
serologic associations with each other, and this is often
the reason why their inclusion in this blood group
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system was initially postulated. Most of these low-
frequency Diego system antigens have only been found
in small kindreds or isolated ethnic groups. While
these antigens and their corresponding antibodiesmay
have clinical significance, they have little or no impact
upon everyday transfusion medicine.4
An altered form of Band 3 protein has been
associated with a hereditary form of red cell
ovalocytosis known as South East Asian ovalocytosis,
and may confer a degree of resistance to invasion by
the malarial parasite Plasmodium falciparum. A
complete absence of Band 3, and, therefore, the
Di(a–b–) phenotype, was thought to be incompatible
with life. However, a severely hydropic, anemic baby
who lacked Band 3 and protein 4.2 was resuscitated
after birth and kept alive by blood transfusions.4
Antibodies to Dia and Dib are generally IgG1 and
IgG3, although some IgM examples have been
reported.5 They are usually produced in response to
RBC exposure and are reactive by antiglobulin
techniques. Rare examples may bind complement
and/or cause in vitro hemolysis.
Anti-Dia has often been implicated in
HDN, but reports of immediate
hemolytic transfusion reactions are
confused by other issues.5 Anti-Dib
usually only cause mild HDN but
there have been a few reports of
delayed transfusion reactions.4,5
Anti-Wra is probably one of the
most commonly seen antibodies to a
low-frequency antigen (and is a
particular bane to one of the authors
during the manufacture of blood
grouping reagents). It is often found
in the sera of individuals who have
produced antibodies to other RBC
antigens. Given the extremely low
frequency of theWra antigen it seems
unlikely that those individuals have
been actually exposed to Wr(a+)
R B C s .
Thus, many examples of anti-Wra
appear to be “naturally occurring” or
stimulated by some-thing other than
RBCs and, in particular, in sera from
individuals who have made multiple
antibodies to low-frequency
antigens. Behavior of the antibodies
varies greatly, perhaps dependent
upon the method of immunization.
Many examples of anti-Wra are IgM, saline-reactive;
others are IgG,reactive by antiglobulin techniques. Still
other examples contain both IgG and IgM
components. Most do not bind complement or cause
in vitro hemolysis. Anti-Wra has often been implicated
in HDN and transfusion reactions.5
Yt Blood Group System
The Yt blood group system (ISBT: YT/011), often
incorrectly referred to as the Cartwright system,
consists of two antigens:Yta and Ytb.6 The antigens are
carried by a GPI-linked glycoprotein named acetyl-
cholinesterase (AChE), which is the product of the
ACHE gene located on chromosome 7 at position q22.
The function of this enzyme in RBCs is not known,
however AChE is a major component of nerve impulse
transmission.4
The genetic polymorphisms that give rise to the
antithetical Yta and Ytb antigens are the result of a
nucleotide substitution in ACHE (1057C>A), which
Table 1 . Diego blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted5 (Caucasians) Notes4,5




DI2 Dib Luebano 1967 >99.9
DI3 Wra Wright 1953 <0.1
DI4 Wrb Fritz 1971 >99.9
DI5 Wda Waldner 1981 <0.1 Found in two
Hutterite families
DI6 Rba Redelberger 1978 <0.1
DI7 WARR Warrior 1991 <0.1 May be unique
to Native Americans
DI8 ELO 1993 <0.1
DI9 Wu Wulfsberg 1976 <0.1
DI10 Bpa Bishop 1966 <0.1
DI11 Moa Moen 1972 <0.1
DI12 Hga Hughes 1983 <0.1
DI13 Vga Van Vugt 1981 <0.1
DI14 Swa Swann 1959 <0.1
DI15 BOW 1988 <0.1
DI16 NFLD Newfoundland 1984 <0.1
DI17 Jna 1967 <0.1
DI18 KREP 1997 <0.1
DI19 Tra Traversu 1975 <0.1 (Provisional)*
DI20 Fra Froese 1978 <0.1
DI21 SW1 1987 <0.1
* ISBT assignment to DI
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produces an amino acid change in the AChE
glycoprotein (His353Asn).4 As seen in Table 2,Yta is of
high frequency in Caucasians and Ytb is of moderately
low frequency. This pattern has been seen in most
populations studied, although the rarity of anti-Ytb has
limited the volume of screening possible.4,5 Studies in
Japan indicate thatYta may be of higher frequency,since
no Yt(a–) individuals were detected in tests on 5000
donors, and no Yt(b+) samples were found among the
70 tested with anti-Ytb.5 On the other hand,Ytb appears
to be more prevalent in Israel,where it was found in 24
to 26 percent of individuals tested. This finding was
accompanied by a relative lowering of the incidence of
Yta. The incidence of the rare Yt(a–b+) phenotype in
Israel was estimated to be 1 in 65, compared to an
estimated 1 in 500 in the United States.5
The Yt(a–b–) phenotype has only been reported
once and was determined to be the result of transient
suppression of Yta in a person who was believed to be
Yt(a+b–). The patient produced an antibody that
reacted with both Yt(a+b–) and Yt(a–b+) cells, and
thus appeared to be anti-Ytab.5
Yt antigens may be absent or have radically
reduced expression on the RBCs of persons with
paroxysmal nocturnal hemoglobinuria (PNH). In
particular, PNH type III RBCs lack most GPI-linked
proteins and therefore may lackYt antigens along with
any other antigens carried by GPI-linked proteins, e.g.,
Dombrock system antigens.4,5
The Yt antigens are variably sensitive to ficin/
papain treatment, i.e., denaturation of antigen has been
reported by some workers while others find them
resistant or even enhanced. The antigens are resistant
to trypsin and chloroquine but can be inactivated by α-
chymotrypsin and DTT (0.2 M).4
TheYta antigen appears to be moderately immuno-
genic and anti-Yta is not an uncommon occurrence in
Yt(a–) persons transfused withYt(a+) RBCs. Examples
of anti-Ytb, on the other hand, are very rare. Anti-Yta is
often found as a single specificity,while anti-Ytb is more
often found in multitransfused patients who have made
other RBC antibodies. Yt antibodies are IgG and react
preferentially by antiglobulin techniques. At least one
example of anti-Yta was reported to bind complement,
but neither in vitro hemolysis nor HDN has been
attributed toYt antibodies.4,5
The clinical significance of Yt antibodies in the
transfusion arena has attracted a great deal of attention
and has caused an even greater amount of conster-
nation. Most work has been done on examples of
anti-Yta, since examples of anti-Ytb are so rare. Over a
dozen studies have been performed on a varying
number of examples of antibody, using a variety of
clinical significance indicators: 51Cr survival studies,
monocyte-monolayer assay (MMA), transfusion of
antigen-positive cells, and/or combinations of the
above. The conclusion:Many examples are benign, i.e.,
not clinically significant. However, other examples
have caused shortened RBC survival of
transfused antigen-positive cells and
at least one has caused a delayed
hemolytic transfusion reaction. In
others, the data are inconclusive.5
Xg Blood Group System
The Xg blood group system (ISBT: XG/012)3,6 is so
named because the gene that encodes the originally
described antigen is carried on the X chromosome.
Until recently, when the CD99 antigen joined the
system, Xga was the sole antigen in this system, a
polymorphism expressed on the Xg glycoprotein,
which is encoded by the XG (PBDX) gene (located on
the X chromosome at position p22.32). The gene
product is a single-pass glycoprotein that may have
biological function as an adhesion molecule, since it
shows a large degree of homology with CD99,a known
adhesion molecule found on a wide variety of tissues.4,5
Since the first report describing CD99 on RBCs and
its variable expression, other phenotypic relationships
were noted: Xg(a+) individuals (male or female) have
high expression of CD99 as do some Xg(a–) males,
while Xg(a–) females and some Xg(a–) males have low
expression of the antigen. This observation, and the
more recent discovery that the structural gene that
encodes CD99 (MIC2) is closely linked to XG, has
resulted in CD99’s being added to the Xg blood group
system.3,5
The most interesting aspect of this system arises
from its direct relationship to the X chromosome.
Because females carry two X chromosomes (XX) and
males only one (XY), the incidence of the Xga antigen
varies radically between the sexes. That the Xg(a–)
Table 2. Yt blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted4 (Caucasians) Notes5
YT1 Yta Cartwright 1956 99.6
YT2 Ytb 1964 8 24–26% in Israelis
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phenotype is fairly common in males and females
indicates that a gene that does not encode the Xga
antigen is also common (where Xg is the gene that
does not express antigen and Xga is the gene that
does). Thus the exhibited phenotypes may be the
result of a variety of genotypes: Xg(a+) women may
have one or two genes expressing Xga, i.e., be Xga/Xga
or Xga/Xg, whereas men only have one X
chromosome,on which the Xga-expressing gene may or
may not be present (Xga/Y or Xg/Y). Since women are
more likely to carry the appropriate gene, the antigen
is found in 89 percent of European women, compared
with 66 percent of men in the same geographic area
(Table 3). Studies on other populations (including
some U.S. studies), indicate that the prevalence of the
Xga antigen is fairly uniform, although a slightly lower
incidence is seen in Chinese and Japanese.4,5
Expression of Xga antigen varies between individ-
uals. However, strength (dose) of antigen is not always
related to phenotype, i.e., Xga/Xga women do not
necessarily exhibit a “double dose” of antigen
compared with Xga/Xgwomen. Further,while some X-
linked genes are affected by “Lyonization” or “X-
chromosome inactivation,” the gene encoding Xga is
not affected, therefore any individual carrying an Xga
gene should express the antigen on their RBCs.
Exceptions to the normal pattern of inheritance have
been described but are extremely uncommon.5
The Xga antigen is denatured by treatment with
ficin/papain, trypsin, and α-chymotrypsin, but is not
affected by DTT (0.2 M). Effects of chloroquine
treatment have not been reported.4,5
Antibodies to Xga have varied
characteristics. Most are IgG, reactive
preferentially by antiglobulin tech-
niques, but others have been
reported that were IgM and were
best detected in room temperature
saline tests. Examples of alloantibody
have been found in persons with a
history of RBC stimulation, while
others appear to be the result of
some other stimulatory mechanism.
Some examples have been reported
to bind complement, but in general
anti-Xga is not clinically important.
Neither transfusion reactions nor
HDN have been attributed to anti-
Xga.4,5
The single reported example of
autoanti-Xga did cause clinical
problems in the form of severe hemolytic anemia. The
IgG, complement-binding autoantibody was seen in a
pregnant woman,who delivered an Xg(a+) infant with
a positive DAT. While the pregnancy may have
exacerbated the severity of the anemia in the mother,
the infant was not anemic and exhibited only mild
bilirubinemia following birth.5
Scianna Blood Group System
The Scianna blood group system (ISBT: SC/013)
currently consists of four defined antigens: Sc1, Sc2,
Sc3, and Rd (Table 4).7 The antigens are carried on a
recently identified RBC adhesion protein called human
erythroid membrane-associated protein (ERMAP).
Earlier workers had identified the antigen-carrying
structure as “Scianna glycoprotein,” which was
encoded by the gene SC. The gene is now called
ERMAP and is located on chromosome 1 at position
p34.1.4,7,8
The Sc1 antigen has a very high frequency in all
populations studied. The overall frequency of its
antithetical antigen, Sc2, is less than 1 percent, but may
be higher in some Mennonite kindreds.4,5 The alleles
are the result of amino acid changes in ERMAP
(Gly57Arg).7
The Sc:–3 phenotype is extremely rare and has only
been described in a handful of individuals, mainly
members of fairly isolated and potentially inbred South
Pacific communities. There are three reports of Sc:–3
persons who produced an antibody that was classified
Table 3. Xg blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted4 (Caucasians) Notes5
XG1 Xga 1962 Females: 89 Similar pattern seen
Males: 66 in other populations;
slightly lower in
Orientals.
XG2 CD99 1981 > 99%*
* Strength of expression varies according to presence or absence of Xga
Table 4. Scianna blood group antigens
First Incidence (%)4
ISBT Conventional Histor ical r epor ted4 (Caucasians) Notes4
SC1 Sc1 Sm, Scianna 1962 > 99
SC2 Sc2 Bua, Bullee 1963 0.3 1% in Northern
Europeans (incidence
may be higher in
Mennonites)
SC3 Sc3 1980 > 99.9
SC4 Rd Rda, Radin 1967 < 0.01 0.5% in Danes; 0.1% in
Jews, Candians, and
African Blacks
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as anti-Sc3. Two were from a South Pacific community,
but the third was in a transfused Caucasian male.4,5 The
DNA of only one person with the Scnull phenotype has
been tested and the null phenotype was found to be
the result of a 2-bp deletion in the ERMAP gene,which
causes a frameshift and produces a version of ERMAP
that does not carry the normal Scianna blood group
antigens.8
The low-frequency antigen Rd (Radin) was recently
added to the Scianna system since the workers who
described the expression of Scianna system antigens
on ERMAP found that Rd was also expressed on the
same protein.7 The antigen is the result of a mutation
in ERMAP that produces a change in the expressed
protein (Pro60Ala). This confirmed earlier data that
indicated that production of Rd was
controlled by a gene on chromo-
some 1, in the same region as SC.
Immunoblotting with anti-Rd had
shown that Rd was carried on a
protein approximately the same
size as the Scianna glycoprotein.5
However, the earlier finding of a
person with Sc:1,2, Rd+ RBCs had
suggested that Rd was not an allele of
Sc1 and Sc2.4,5
The Sc1 and Sc2 antigens are resistant to treatment
with ficin/papain, trypsin, and α-chymotrypsin,
whereas treatment with DTT (0.2 M) renders the
antigens undetectable in serologic tests. Chloroquine
treatment has no effect upon Sc2 or Sc3 and it is
presumed that Sc1 behaves in a similar fashion.4,5 The
Rd antigen differs in that the effect of trypsin and α-
chymotrypsin treatment is variable.
Antibodies to Scianna system antigens are usually
IgG, and are reactive preferentially with antiglobulin
techniques, although a few examples of saline-reactive
anti-Sc2 have been reported. The antibodies may or
may not bind complement, but they do not cause in
vitro hemolysis. Typically, these antibodies are
produced in response to RBC stimulation (transfusion
or pregnancy), although some examples of anti-Sc2
appear to be “naturally occurring.” Although data are
limited, Scianna system antibodies have not been
reported to cause severe transfusion reactions; in
general, they cause mild, if any, HDN; but they may
cause a positive DAT.4,5 However, anti-Rd has caused
severe HDN. Autoantibodies with Sc1 and Sc3
specificity have also been described and may be a
consequence of antigen suppression in association
with a variety of disease states. Interestingly, one well-
investigated example of autoanti-Sc1 was reactive only
in serum and not in plasma.4,5
Dombrock Blood Group System
The five antigens of the Dombrock blood group
system (ISBT: DO/014)5 were described long before
they came together as a group (Table 5). While it had
been noted that there were serologic and phenotypic
relationships between three of the antigens prior to
forming the Dombrock system,5 it was the exciting
finding that Gy(a–) RBCs are Do(a–b–) that linked the
five antigens together as members of the Dombrock
blood group system.
The antigens of the Dombrock system are carried
on the Dombrock glycoprotein, a GPI-linked
glycoprotein. The gene itself,DO, has been reported to
be located at 12p13.2–p12.1 and was recently cloned.4
Doa and Dob are the only antithetical, polymorphic
antigens in the Dombrock system. The Doa antigen, in
particular, demonstrates a wide variation in incidence
between ethnic groups,while Dob is more consistently
of higher frequency. The other three antigens of the
Dombrock system, Gya, Hy, and Joa, are of extremely
high frequency in all populations.4,7 The rare Gy(a–)
phenotype is considered the null phenotype within the
Dombrock system. Until recently, when a Black
proband was found, it had only been found in
Caucasians and Japanese. Such individuals lack all
other Dombrock system antigens, i.e., their red cell
phenotype is Do(a–b–), Gy(a–), Hy–, and Jo(a–). The
absence of the DO glycoprotein is apparent in persons
with type III PNH, whose RBCs either lack or have
markedly reduced levels of all GPI-linked proteins.4,5
The Hy– and Jo(a–) phenotypes are found
exclusively in Blacks. Hy– individuals phenotype as
Do(a–b+w),they are Jo(a–),and they have a significantly
weakened expression of Gya. Persons who are Jo(a–)
Table 5. Dombrock blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted4 (Caucasians) Notes4,5
DO1 Doa Dombrock 1965 67 55% in Blacks;
24% in Japanese;
14% in Thais
DO2 Dob 1973 83 89% in Blacks
DO3 Gya Gregory 1967 > 99.9
DO4 Hy Holley 1970 > 99.9
DO5 Joa Joseph 1972 > 99.9
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exhibit normal Gya antigen expression but have
weakened expression of Hy and the other Dombrock
antigens (if the genes for Doa/Dob are present).4,5 When
these phenotypic observations (Table 6) and the newer
biochemical information were analyzed, it was possible
to finally rationalize the five antigens into the formal
blood group system known today.4
All Dombrock system antigens are resistant to
treatment with ficin/papain, they are sensitive to and
weakened by trypsin and α-chymotrypsin, respectively,
and they are sensitive to DTT (0.2 M) and resistant to
chloroquine.4
Doa and Dob appear to be poor immunogens.
Antibodies are rarely found and are even more rarely
found as a single specificity, i.e., they are generally only
found in multitransfused individuals with a number of
antibodies to common antigens.4,5 The antibodies are
invariably the consequence of RBC stimulation, are
predominantly IgG, and are reactive almost exclusively
by antiglobulin techniques. The antibodies do not bind
complement and do not cause in vitro hemolysis.
Antibodies to Doa and Dob have been implicated in
transfusion reactions but have not been shown to
cause clinical HDN.4 Anti-Doa has a reputation as an
antibody that may disappear in vivo, becoming
undetectable by conventional serologic tests—a
particularly nasty characteristic more often seen with
Kidd system antibodies.
The Gya antigen is highly immunogenic and usually
results in production of an IgG antibody, which reacts
preferentially by antiglobulin techniques. Anti-Gya does
not bind complement and does not cause in vitro
hemolysis. Moderate transfusion reactions due to anti-
Gya have been reported, but no clinically significant
HDN has yet been documented.4,5
Colton Blood Group System
The Colton blood group system (ISBT: CO/015)
consists of just three antigens: Coa, Cob, and Co3.5 The
Coa and Cob antigens are carried on a multi-pass
membrane glycoprotein called Aquaporin-1 (AQP1) or
Channel Forming Integral Protein (CHIP-1). The gene
that encodes this water transport protein is located on
chromosome 7 at position p14 and is formally called
AQP1 (Aquaporin-1). The Co3 antigen is always
present when Coa and/or Cob are expressed, i.e., the
genes that encode Coa and Cob also encode for the
production of Co3. The location of the Co3 antigen on
CHIP-1 is yet to be defined. Studies on AQP1 have
revealed at least six different molecular bases for the
Co(a–b–) or Co:–3 phenotype.4 See Table 7 for
antigens and frequencies.
Coa and Cob are antithetical, the result of a
nucleotide substitution in AQP1 (134C>T) that leads to
an amino acid change in CHIP-1 (Ala45Val). Coa is of
high frequency in all populations. The Cob antigen
shows a little more variation between ethnic groups,
but is generally found in 8 to10 percent of individuals.
The Co3 antigen is of extremely high frequency.
Absence of Co3 results in the null phenotype
[Co(a–b–)],which has only been described in a handful
of people.4,7 Interestingly, even though such persons
appear to lack an apparently critical water transport
protein, i.e., CHIP-1, they have no significant medical
conditions under normal circumstances.5
Antigens in the Colton system are resistant to
treatment with ficin/papain, trypsin, α-chymotrypsin,
chloroquine, and DTT (0.2 M).4
Antibodies to Colton antigens are usually the result
of exposure to RBCs, from either transfusion or
pregnancy. The antibodies produced usually are IgG in
nature and react preferentially by antiglobulin
techniques. Some examples may bind complement,
but in vitro hemolysis is rarely encountered.4,5
Anti-Coa is most often seen as a single specificity
and has been reported to cause transfusion reactions
and HDN. On the other hand, anti-Cob is more often
seen in persons with other RBC antibodies and has also
been documented as causing transfusion reactions, but
has only been reported to cause mild HDN.5
Anti-Co3 is only seen in persons with the Co(a–b–)
phenotype. The antibody reacts as if it were anti-Coab,
Table 7. Colton blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted5 (Caucasians)
CO1 Coa Colton 1967 99.7
CO2 Cob 1970 9.7
CO3 Co3 Coab 1974 > 99.9
Table 6. Dombrock system phenotypes
Antigen
Phenotype Doa Dob Gya Hy Joa
Do(a+b–) + 0 + + +
Do(a+b+) + + + + +
Do(a–b+) 0 + + + +
Gy(a–) 0 0 0 0 0
Hy– 0 +w +w 0 0
Jo(a–) +w 0/+w + +w 0
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an apparently inseparable specificity. It has been
shown to be clinically significant in transfusion and it
can cause HDN.5
LW Blood Group System
The LW (Landsteiner-Wiener) blood group system
(ISBT:LW/016)6 is probably most notable for its history.
In some early experiments, Landsteiner and Wiener
produced an antibody in rabbits and guinea pigs that
appeared to have the same specificity as human anti-D.
Experiments by later workers proved that the original
antibody was not anti-D but that it did have the same
specificity as that seen in two D+ people. These
antibodies could be adsorbed to exhaustion using D–
cells and were therefore not anti-D. For a time, this
specificity was known as anti-D-like, but was later
changed to anti-LW to reduce confusion.5
Over the intervening decades, the terminology for
this series of antigens has evolved through several
formats in an attempt to rationalize the observed
serologic reactions and postulated phenotypes: the
original terminology attempted to convey the
phenotypic relationships that were noted with the D
antigen. Thus the current ISBT terminology starts with
LW5, since the now obsolete early ISBT numbers had
been assigned to what are more properly called LW
phenotypes.5,6
There are three antigens currently assigned to the
LW system: LWa, LWab, and LWb (Table 8).6 They are
carried on a single-pass glycoprotein called LW
glycoprotein (ICAM-4), the biological function of
which is as an intracellular adhesion molecule. The
glycoprotein is encoded by the LW gene, which is
located on chromosome 19 at position 13.3.4
LWa and LWb are antithetical, the result of a single
nucleotide substitution on the LW gene (308A>G) that
produces an amino acid change on the LW
glycoprotein (Gln70Arg). The molecular basis for LWab
antigen expression has not yet been determined. The
molecular basis of the only known genetic
LW(a–b–ab–) phenotype, found in one antenatal
patient and her brother, is a 10-bp deletion in exon 1 of
LW. This results in a truncated glycoprotein without
transmembrane and cytoplasmic domains.4
LWa and LWab have very high frequency in all
populations tested (albeit,mostly Europeans). The LWb
antigen is found in less than 1 percent of most
Europeans, but is present in 8 percent of Estonians, 6
percent of Finns, and 4 percent of Poles. As noted
above, only two individuals with a persistent LW(a–b–)
phenotype have been described. Persons with the
Rhnull phenotype are also negative for all LW system
antigens, a phenomenon that reiterates the relationship
between Rh antigen expression and LW antigen
expression on RBCs (more details follow).4,5
The LW system antigens are resistant to treatment
with ficin/papain, trypsin, and chloroquine. They may
be weakened by α-chymotrypsin and are denatured by
DTT (0.2 M).4,5
LW antigen expression may be transiently
depressed during pregnancy and in a variety of disease
states, including Hodgkins disease, lymphoma, leuke-
mia, and sarcoma. The development of autoantibodies
following antigen suppression is not uncommon.
Examples of autoanti-LWa and autoanti-LWab have been
documented, a scenario which has been known to
confound serologists. In these situations, it may be
difficult to serologically differentiate between alloanti-
bodies and autoantibodies in this system without a
series of chronologically distinct specimens, i.e.,
predisease, during disease, and postdisease. Antigen
suppression may be so drastic that the antigens are
serologically undetectable.4,5
As alluded to earlier, expression of LW antigens is
greatly influenced by the presence or absence of Rh
protein. In particular, the strength of expression of LW
antigens is directly related to the presence or absence
of D antigen. Adults with D+ RBCs have a stronger
expression of LW antigens than those with D– RBCs.
Expression is also influenced by the relative strength of
D antigen present, i.e.,persons with Rh haplotypes that
have the highest expression of D antigen, e.g., R2R2,
have the strongest expression of LW antigens. This
phenomenon can lead to misidentification of anti-D,
anti-LWa, and LWab. When an antibody
identification panel is tested and all D+
samples are moderately or weakly
reactive, the conclusion that anti-D is
present is perfectly logical, until the
worker notes that the patient is D+.
This may be the correct inter-
pretation, if the patient has a D–
Table 8. LW (Landsteiner-Wiener) blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted4 (Caucasians) Notes4,5
LW5 LWa LW, Rh25 1961 > 99
LW6 LWab LW1, LW2, LW3 1982 > 99
LW7 LWb Nea 1981 < 1 8% in Estonians;
6% in Finns;
4% in Poles
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phenotype, or if the patient can be shown to have a
partial D phenotype. However, it is also possible that
the reactivity pattern seen is due to a relatively weak
anti-LW that is reactive with those cells with stronger
expression of LW, i.e., those that are D+.5 Anti-LW can
be distinguished from anti-D by testing with DTT-
treated RBCs. Testing with RBCs from a cord sample
can also aid in identification because on cord RBCs LW
is strongly expressed on both D– and D+ phenotypes.
Antibodies to LW system antigens are usually IgG
and reactive preferentially by antiglobulin techniques.
The antibodies are usually produced in response to
exposure to RBCs,but have been found in persons with
no apparent exposure. They do not bind complement
and do not cause in vitro hemolysis. LW system
antibodies appear to have little or no clinical signi-
ficance, although data are scarce. While these anti-
bodies have been reported to cause a positive DAT in
newborns, clinical HDN has not been reported.
Clinicians who must“transfuse against”examples of LW
system antibodies will often select Rh negative (D–)
units for transfusion, since these RBCs have the weakest
expression of LW antigens. To date, this practice has
always resulted in a satisfactory transfusion outcome.4,5
Indian Blood Group System
The Indian blood group system (ISBT: IN/023)
consists of two antithetical antigens: Ina and Inb.6 The
antigens are carried by CD44, a single-pass membrane
glycoprotein that is encoded by the CD44 gene on
chromosome 11 at position p13. The biological
function of CD44 is as a leukocyte homing receptor
and cellular adhesion molecule. The protein is
widespread and found in a large variety of tissues.4
The Ina and Inb polymorphisms arise from a
nucleotide substitution in the CD44 gene (252C>G)
that results in an amino acid change on the CD44
glycoprotein (Pro46Arg).4,5 As seen in Table 9, the low-
frequency Ina antigen is extremely rare in Europeans,
but it has a low prevalence in Indians and is found most
commonly in Iranians and Arabs.5 Persons with the
In(a+b–) phenotype have only been found in these
ethnic groups. The extremely rare In(a–b–) phenotype
has only been described in one individual,who had an
unusual presentation of congenital dyserythropoietic
anemia (CDA) that produced RBCs that were deficient
in CD44. Interestingly, the patient also typed Co(a–b–)
and had a weak expression of LW antigens.5
The Indian system antigens are sensitive to
treatment with ficin/papain, trypsin, α-chymotrypsin,
and DTT (0.2 M), but are resistant to chloroquine.4,5
The susceptibility of the antigens to ficin/papain is
perhaps one of the most useful tools in differentiating
anti-Inb from many of the other antibodies to high-
frequency antigens.
This apparently simple blood group system is
complicated by its relationships to the high-frequency
antigen AnWj and the In(Lu) gene. There is convincing
evidence to indicate that the AnWj antigen is carried
on CD44 and it may eventually be added to the Indian
blood group system. Expression of AnWj can vary in
strength between individuals. Unlike Ina and Inb,AnWj
is not affected by treatment with ficin/papain, trypsin,
or α-chymotrypsin, and is therefore presumably on an
area of CD44 that is not cleaved by those enzymes.
Antibodies to AnWj are usually IgG, and are reactive by
antiglobulin techniques. Only two examples of
alloanti-AnWj have been reported.Others appear to be
autoantibodies, with concurrent weakening of RBC
antigens as a consequence of reduced expression of
CD44 in a variety of disease states. Examples of anti-
AnWj have been shown to cause transfusion reactions.
Anti-AnWj has not been implicated in HDN.4,5 This is
not surprising because the RBCs of newborns do not
express AnWj. The switch from AnWj– to AnWj+
occurs early in life, between days 3 and 46 after birth.
Persons who inherit the In(Lu) gene (the
dominant inhibitor of Lutheran system antigens)
exhibit a broad weakening or suppression of Lutheran
and related RBC antigens. CD44 on RBCs is suppressed
in the presence of In(Lu), although expression in other
tissues is normal. These RBCs express very little Inb or
AnWj antigen (or Ina, if present). Sometimes the
antigens are only detectable in adsorption/elution
studies.4,5
The Indian system antigens are good immunogens
and many examples of the antibodies
have been reported. Most are IgG,
reacting preferentially by antiglobulin
techniques, although some saline-
reactive examples have also been
reported (possibly indicating the
presence of IgM antibodies). The
Table 9. Indian blood group antigens
First Incidence (%)5
ISBT Conventional Histor ical r epor ted5 (Caucasians) Notes5
IN1 Ina 1973 < 0.1 4% in Indians;
11% in Iranians;
12% in Arabs
IN2 Inb Salis 1975 > 99.9
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antibodies do not bind complement and do not cause
in vitro hemolysis. Anti-Ina has not been reported to
cause transfusion reactions, although data are scarce,
probably because In(a+) donors are scarce in most
populations. However, in vivo survival experiments
indicate that two examples of the antibody rapidly
cleared In(a+) RBCs. Anti-Inb may cause anything from
no reaction to rapid or delayed hemolytic reactions.
Neither specificity has been reported to cause clinical
HDN,although the RBCs of a number of infants born to
mothers with anti-Inb had a positive DAT. On the other
hand, the RBCs of some infants were DAT negative and
maternal anti-Inb was not detectable in the infants’ sera.
The lack of significant HDN as a result of these
antibodies may be related to the presence of CD44 on
many other tissues, particularly the placenta, which
may have a preemptive absorption effect, thereby
protecting the fetus.5
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